Solid Tumors

Combination Strategies for Jump-Starting the Immune Response

CHECKPOINT INHIBITORS have dramatically changed the landscape of the treatment of melanoma, lung, bladder, and other cancers...

Lung Cancer

Checkpoint Inhibitors May Prove to Be Effective in Mesothelioma

CHECKPOINT INHIBITION was effective against malignant pleural mesothelioma in the MAPS-2 study of the French Cooperative Thoracic Intergroup...

Supportive Care

Are Wearable Physical Activity Monitors Coming of Age in Oncology?

COMMERCIALLY AVAILABLE wearable physical activity monitors have been making their way into clinical research in recent years; however, most studies...


Advertisement

More Top Stories

Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on GEJ Adenocarcinoma: Results From the FLOT4-AIO Trial

Breast Cancer

Digital Tomosynthesis vs Mammography in Unmasking Breast Cancer

DIGITAL TOMOSYNTHESIS is rapidly replacing full-field digital mammography, because “it allows a more efficient diagnostic workflow and leads to a more confident interpretation,” according to Elizabeth A. Morris, MD, FACR, Chief of the Breast Imaging Service, Memorial Sloan Kettering Cancer...

Advertisement

Poor Social Functioning in Adolescent and Young Adult Cancer Survivors

A new study indicates many young adults who survived the disease struggle with “getting back to normal” as much as 2 years after their initial diagnosis. The longitudinal study, published by Husson et al in Cancer, is among the first seeking to understand the social functioning among...

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Kidney Cancer

Atezolizumab/Bevacizumab Moves Forward in Metastatic Renal Cell Carcinoma

THE COMBINATION of atezolizumab (Tecentriq) plus bevacizumab (Avastin) showed promising results as first-line treatment of patients with metastatic renal cell carcinoma, according to a phase II trial called IMmotion 150. Based on these results, the phase III IMmotion 151 trial is comparing...

Leukemia

Pivotal CAR T-Cell Data Reported in Relapsed/Refractory B-Cell ALL

UPDATED RESULTS from the ELIANA clinical trial of CTL019 (tisagenlecleucel)—an investigational chimeric antigen receptor (CAR) T-cell therapy—found that remission rates are maintained at 6 months in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia....

Classifying Gastric Cancers by Subtype May Provide Tailored Treatment Options

Gastric cancer is the third leading cause of cancer death in both men and women worldwide. In 2014, The Cancer Genome Atlas (TCGA) project discovered there are four molecular subtypes of gastric cancer: Epstein-Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and...

Issues in Oncology

Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates

Supportive Care

Are Wearable Physical Activity Monitors Coming of Age in Oncology?

COMMERCIALLY AVAILABLE wearable physical activity monitors have been making their way into clinical research in recent years; however, most studies on these devices have been related to non-cancer conditions including obesity, depression, and physical activity. Their application in the field of...

Advertisement

Genetic Study Identifies Susceptibility Loci Modifying Risk for Breast Cancer After Radiation Therapy for Childhood Cancer

As reported in the Journal of the National Cancer Institute, Morton et al have identified gene loci associated with radiation-related risk of breast cancer in survivors of childhood cancer. Study Details The study was a genome-wide association study of breast cancer in female survivors of...